Literature DB >> 29663336

Melanoma: What do all the mutations mean?

Elizabeth J Davis1, Douglas B Johnson1, Jeffrey A Sosman2, Sunandana Chandra2.   

Abstract

Melanoma is one of the most highly mutated malignancies, largely as a function of its generation through ultraviolet light and other mutational processes. The wide array of mutations in both "driver" and "passenger" genes can present a confusing array of data for practitioners, particularly within the context of the recent revolutions in targeted and immune therapy. Although mutations in BRAF V600 clearly confer sensitivity to BRAF and mitogen-activated protein kinase kinase (MEK) inhibitors, the clinical implications of most other mutations are less often discussed and understood. In this review, we provide an overview of the high-frequency genomic alterations and their prognostic and therapeutic relevance in melanoma.
© 2018 American Cancer Society.

Entities:  

Keywords:  BRAF; KIT; NRAS; cyclin-dependent kinase inhibitor 2A (CDKN2A); melanoma; mutation; programmed cell death protein 1 (PD-1)

Mesh:

Substances:

Year:  2018        PMID: 29663336      PMCID: PMC6191351          DOI: 10.1002/cncr.31345

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  92 in total

1.  BRAF mutations and KIT aberrations and their clinicopathological correlation in 202 Korean melanomas.

Authors:  Sun A Jin; Seung Min Chun; Yoo Duk Choi; Sun-Seog Kweon; Sung Taek Jung; Hyun Jeong Shim; Sook Jung Yun
Journal:  J Invest Dermatol       Date:  2012-09-27       Impact factor: 8.551

2.  BRAF inhibitor activity in V600R metastatic melanoma--response.

Authors:  Oliver Klein; Arthur Clements; Alexander M Menzies; Sandra O'Toole; Richard F Kefford; Georgina V Long
Journal:  Eur J Cancer       Date:  2013-03-13       Impact factor: 9.162

3.  Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.

Authors:  Alexander M Menzies; Iwei Yeh; Thomas Botton; Boris C Bastian; Richard A Scolyer; Georgina V Long
Journal:  Pigment Cell Melanoma Res       Date:  2015-07-03       Impact factor: 4.693

4.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

5.  Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.

Authors:  Douglas B Johnson; Alexander M Menzies; Lisa Zimmer; Zeynep Eroglu; Fei Ye; Shilin Zhao; Helen Rizos; Antje Sucker; Richard A Scolyer; Ralf Gutzmer; Helen Gogas; Richard F Kefford; John F Thompson; Jürgen C Becker; Carola Berking; Friederike Egberts; Carmen Loquai; Simone M Goldinger; Gulietta M Pupo; Willy Hugo; Xiangju Kong; Levi A Garraway; Jeffrey A Sosman; Antoni Ribas; Roger S Lo; Georgina V Long; Dirk Schadendorf
Journal:  Eur J Cancer       Date:  2015-11-19       Impact factor: 9.162

6.  An immunogenic personal neoantigen vaccine for patients with melanoma.

Authors:  Patrick A Ott; Zhuting Hu; Derin B Keskin; Sachet A Shukla; Jing Sun; David J Bozym; Wandi Zhang; Adrienne Luoma; Anita Giobbie-Hurder; Lauren Peter; Christina Chen; Oriol Olive; Todd A Carter; Shuqiang Li; David J Lieb; Thomas Eisenhaure; Evisa Gjini; Jonathan Stevens; William J Lane; Indu Javeri; Kaliappanadar Nellaiappan; Andres M Salazar; Heather Daley; Michael Seaman; Elizabeth I Buchbinder; Charles H Yoon; Maegan Harden; Niall Lennon; Stacey Gabriel; Scott J Rodig; Dan H Barouch; Jon C Aster; Gad Getz; Kai Wucherpfennig; Donna Neuberg; Jerome Ritz; Eric S Lander; Edward F Fritsch; Nir Hacohen; Catherine J Wu
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

7.  Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin.

Authors:  Iñigo Martincorena; Amit Roshan; Moritz Gerstung; Peter Ellis; Peter Van Loo; Stuart McLaren; David C Wedge; Anthony Fullam; Ludmil B Alexandrov; Jose M Tubio; Lucy Stebbings; Andrew Menzies; Sara Widaa; Michael R Stratton; Philip H Jones; Peter J Campbell
Journal:  Science       Date:  2015-05-22       Impact factor: 47.728

8.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.

Authors:  Zachary R Chalmers; Caitlin F Connelly; David Fabrizio; Laurie Gay; Siraj M Ali; Riley Ennis; Alexa Schrock; Brittany Campbell; Adam Shlien; Juliann Chmielecki; Franklin Huang; Yuting He; James Sun; Uri Tabori; Mark Kennedy; Daniel S Lieber; Steven Roels; Jared White; Geoffrey A Otto; Jeffrey S Ross; Levi Garraway; Vincent A Miller; Phillip J Stephens; Garrett M Frampton
Journal:  Genome Med       Date:  2017-04-19       Impact factor: 11.117

9.  An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background.

Authors:  Devarati Mitra; Xi Luo; Ann Morgan; Jin Wang; Mai P Hoang; Jennifer Lo; Candace R Guerrero; Jochen K Lennerz; Martin C Mihm; Jennifer A Wargo; Kathleen C Robinson; Suprabha P Devi; Jillian C Vanover; John A D'Orazio; Martin McMahon; Marcus W Bosenberg; Kevin M Haigis; Daniel A Haber; Yinsheng Wang; David E Fisher
Journal:  Nature       Date:  2012-10-31       Impact factor: 49.962

10.  Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.

Authors:  Michael Krauthammer; Yong Kong; Antonella Bacchiocchi; Perry Evans; Natapol Pornputtapong; Cen Wu; Jamie P. McCusker; Shuangge Ma; Elaine Cheng; Robert Straub; Merdan Serin; Marcus Bosenberg; Stephan Ariyan; Deepak Narayan; Mario Sznol; Harriet M Kluger; Shrikant Mane; Joseph Schlessinger; Richard P Lifton; Ruth Halaban
Journal:  Nat Genet       Date:  2015-07-27       Impact factor: 41.307

View more
  33 in total

1.  Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction.

Authors:  Alexandra Landras; Coralie Reger de Moura; Bruno O Villoutreix; Maxime Battistella; Aurélie Sadoux; Nicolas Dumaz; Suzanne Menashi; Juan Fernández-Recio; Céleste Lebbé; Samia Mourah
Journal:  Oncogene       Date:  2022-02-26       Impact factor: 9.867

2.  Novel insights into the pathogenesis and treatment of NRAS mutant melanoma.

Authors:  Jeffrey Zhao; Carlos Galvez; Kathryn Eby Beckermann; Douglas B Johnson; Jeffrey A Sosman
Journal:  Expert Rev Precis Med Drug Dev       Date:  2021-08-11

3.  Rare c-KIT c.1926delA and c.1936T>G Mutations in Exon 13 Define Imatinib Resistance in Gastrointestinal Stromal Tumors and Melanoma Patients: Case Reports and Cell Experiments.

Authors:  Chi Yan; Chengzhi Zhao; Ke Yang; Hongyan Zhou; Limin Jing; Weixing Zhao; Wenguang Dou; Qingxin Xia; Jie Ma; Bing Wei; Yongjun Guo
Journal:  Front Mol Biosci       Date:  2022-06-02

4.  TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.

Authors:  Carl M Thielmann; Johanna Matull; Anne Zaremba; Rajmohan Murali; Eleftheria Chorti; Georg Lodde; Philipp Jansen; Rudolf Herbst; Patrick Terheyden; Jochen Utikal; Claudia Pföhler; Jens Ulrich; Alexander Kreuter; Peter Mohr; Ralf Gutzmer; Friedegund Meier; Edgar Dippel; Michael Weichenthal; Julia Kretz; Inga Möller; Antje Sucker; Annette Paschen; Elisabeth Livingstone; Lisa Zimmer; Eva Hadaschik; Selma Ugurel; Dirk Schadendorf; Klaus G Griewank
Journal:  Eur J Cancer       Date:  2021-12-20       Impact factor: 10.002

5.  Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis.

Authors:  Yang Zheng; Hongyan Sun; Lele Cong; Chenlu Liu; Qian Sun; Nan Wu; Xianling Cong
Journal:  J Oncol       Date:  2021-05-04       Impact factor: 4.375

Review 6.  Metabolic Plasticity of Melanoma Cells and Their Crosstalk With Tumor Microenvironment.

Authors:  Angelica Avagliano; Giuseppe Fiume; Alessandra Pelagalli; Gennaro Sanità; Maria Rosaria Ruocco; Stefania Montagnani; Alessandro Arcucci
Journal:  Front Oncol       Date:  2020-05-22       Impact factor: 6.244

Review 7.  Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?

Authors:  Stephanie McKenna; Lucía García-Gutiérrez
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

Review 8.  Many Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas.

Authors:  Jiri Vachtenheim; Lubica Ondrušová
Journal:  Life (Basel)       Date:  2021-05-05

Review 9.  Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma.

Authors:  Magali Boyer; Laure Cayrefourcq; Olivier Dereure; Laurent Meunier; Ondine Becquart; Catherine Alix-Panabières
Journal:  Cancers (Basel)       Date:  2020-04-13       Impact factor: 6.639

Review 10.  The Importance of the Right Framework: Mitogen-Activated Protein Kinase Pathway and the Scaffolding Protein PTPIP51.

Authors:  Eric Dietel; Alexander Brobeil; Stefan Gattenlöhner; Monika Wimmer
Journal:  Int J Mol Sci       Date:  2018-10-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.